Breaks Categories: News

WednesdaySep 22, 2021 2:08 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA"). The clinical trial is designed to evaluate the efficacy of TRYP’s clinical candidate, TRP-8802, for the treatment of patients with eating disorders. TRYP is working with Jennifer Miller, MD, from the University of Florida, to conduct the trial as well as evaluate its oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. The IND application outlines specifics in regard to the safety of…

Continue Reading

WednesdaySep 22, 2021 12:30 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Healthcare Small Cap Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 pm ET on Wednesday, Sept. 29, 2021. The event is scheduled to take place from Sept. 29-30, 2021. Investors interested in joining the Vivos presentation should visit https://ibn.fm/JFY3h to register for a free spectator pass. A replay of the presentation will be available for view…

Continue Reading

FridaySep 17, 2021 12:33 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Names World-Renowned Thought Leader as Advisory Board Member

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that Dr. Osama Hamdy, MD, PhD, has joined its advisory board. Hamdy will act as a consultant and will provide invaluable input regarding key opinion leader studies in both the diabetes and metabolic health fields using Nemaura’s glucose monitoring technology. An acclaimed endocrinologist, Hamdy is medical director of the Obesity Clinic Program at the Joslin Diabetes Center; he is also an associate professor of medicine at Harvard Medical School. He has built a stellar reputation as…

Continue Reading

FridaySep 17, 2021 12:09 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM), BayMedica Slated to Participate in Tribe Public Webinar

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has announced that its CEO Eric A. Adams will be a featured presenter at Tribe Public’s upcoming complimentary ZOOM presentation titled “Accelerating The Commercialization of Rare Cannabinoids.” The webinar is scheduled to begin on Sept. 21, 2021, at 11.30 a.m. ET. In addition to Adams, BayMedica Inc. cofounder Shane Johnson will also present during the event. Adams and Johnson’s presentation will be hosted by Tribe Public managing member John F. Heerdink Jr., who will field live questions and pass those on to the presenters. In…

Continue Reading

FridaySep 17, 2021 9:56 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Exec to Participate in Upcoming in Mental Health Virtual Conference

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has announced that president and CEO Kelsey Ramsden will be participating in the Advances in Mental Health Virtual Conference. The one-day conference, presented by Maxim Group LLC and hosted by M-Vest, is scheduled for Sept. 22, 2021. Ramsden will be a panel member in two separate sessions held during the virtual event. The panels, which are part of the “Disruptors in the Mental Health Space” series, are titled “The Second Generation – Beyond Psilocybin and MDMA”and “Delivery, Manufacturing and Technology” and will…

Continue Reading

ThursdaySep 16, 2021 9:35 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Partnership Digital Therapeutics Alliance

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, is joining the Digital Therapeutics Alliance. A nonprofit association of industry leaders, the alliance is dedicated to driving awareness and adoption of digital therapies. MINDCURE announced that, as part of the alliance, the company is committed to providing value and reimbursement, policy and regulation, and awareness to educate the broader health-care industry about the benefits of including new technologies in current treatment regimes. Collaboration with the alliance is a strategic move as MINDCURE works to position iSTRYM, its proprietary software application, as…

Continue Reading

MondaySep 13, 2021 11:05 am

BioMedNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Announces Engagement of Oak Hill Financial for Investor Relations, Advisory Services

Avricore Health (TSX.V: AVCR)(OTCQB: AVCRF) today announced that it has appointed Oak Hill Financial Services Inc. to provide the company with investor relations and advisory services. Toronto-based Oak Hill is a financial services provider that assists companies in enhancing their corporate profile. Under the agreement, Avricore will pay Oak Hill a fee of $12,000 per month for an initial three months. Oak Hill will provide services such as drafting marketing materials and reaching out to its Canadian investor network to expand Avricore’s visibility in the financial community. “We are really excited by Oak Hill’s track record of success in our sector,…

Continue Reading

FridaySep 10, 2021 10:24 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright 23rd Annual Global Investment Conference

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that its president and CEO Eric. A. Adams will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The event is slated to be held virtually from Sept. 13-15, 2021. Adams’ presentation will be available on-demand beginning at 1:00 p.m. ET on Sept. 13, accessible from the H.C. Wainwright events platform at HCW Events. An archived replay will be available on the company’s website immediately following the conference for a period of 90 days. In addition, InMed’s management team will be conducting…

Continue Reading

WednesdaySep 08, 2021 10:46 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) to Participate in H.C. Wainwright Global Investment Conference

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, has announced that it will featured at the upcoming H.C. Wainwright 23rd annual Global Investment Conference. The three-day conference is scheduled to begin Sept. 13 and runs through Sept. 15, 2021. MINDCURE president and CEO Kelsey Ramsden will present an overview of the company on Sept. 13, 2021, at 7 a.m. ET. The presentation will be available for interested viewers for 90 days following the conference. To view the presentation, visit https://ibn.fm/whfnm To view the full press release, visit https://ibn.fm/IyoMF About Mind Cure Health…

Continue Reading

TuesdaySep 07, 2021 9:32 am

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase in Subsidiary Holding

AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary AnPac Bio-Medical Science (Lishui) Co. Ltd. has increased its holding in AnPai (Shanghai) Healthcare Management Consultant Co. Ltd., one of its subsidiaries; the increase came after approval was granted by the company audit committee and board of directors. The company announced that in late August 2021 it finalized the share structure registration amendment with the local Administration Management Bureau. Before making the decision, company officials conducted rigorous due diligence that included obtaining financial and legal audits and appraisals by a qualified appraiser. AnPac Bio-Medical Science is a biotechnology company with operations in China and…

Continue Reading